China-based biotechnology company 3SBio has acquired the entire share capital of Italian group Sirton Pharmaceuticals.
"Expanding 3SBio's footprint in key developed markets is a core strategic objective for 3SBio," said Dr. Jing Lou, Chairman and Chief Executive Office of 3SBio. He continued: "With a team of experienced professionals and a client base of leading pharmaceutical companies, Sirton provides 3SBio with a solid base to manufacture, develop and market pharmaceutical products in Europe. We look forward to working with Sirton's management team and clients to provide safe, affordable and innovative medicines to patients across Europe."
Mr. Giorgio Biella, Managing Director of Sirton, said: "My colleagues and I look forward to working with the team from 3SBio as we pursue our common goal of manufacturing high-quality medicines for international markets." He continued, "3SBio's proven R&D capabilities, global business development strategies, and strong financial position will complement Sirton's existing client relationships and manufacturing experience in Europe."